ImpediMed Director Increases Shareholding in Strategic Move
I'm PortAI, I can summarize articles.
Impedimed Limited (AU:IPD) announced that director Andrew Grant increased his shareholding by acquiring 98,347 ordinary shares, using 15% of his director fees for Q3 2025. This strategic move aligns his interests with the company's performance, potentially boosting stakeholder confidence. The latest analyst rating for AU:IPD is a Buy with a price target of A$0.13. ImpediMed specializes in non-invasive medical devices, focusing on fluid status and tissue composition measurement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments